Cargando…

A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis

Overdiagnosis of breast cancer, defined as diagnosing a cancer that would otherwise not cause symptoms or death in a patient's lifetime, costs U.S. health care system over $1.2 billion annually. Overdiagnosis rates, estimated to be around 10%–40%, may be reduced if indolent breast findings can...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunç, Sait, Alagoz, Oguzhan, Burnside, Elizabeth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313854/
https://www.ncbi.nlm.nih.gov/pubmed/35915601
http://dx.doi.org/10.1111/poms.13691
_version_ 1784754176182452224
author Tunç, Sait
Alagoz, Oguzhan
Burnside, Elizabeth S.
author_facet Tunç, Sait
Alagoz, Oguzhan
Burnside, Elizabeth S.
author_sort Tunç, Sait
collection PubMed
description Overdiagnosis of breast cancer, defined as diagnosing a cancer that would otherwise not cause symptoms or death in a patient's lifetime, costs U.S. health care system over $1.2 billion annually. Overdiagnosis rates, estimated to be around 10%–40%, may be reduced if indolent breast findings can be identified and followed with noninvasive imaging rather than biopsy. However, there are no validated guidelines for radiologists to decide when to choose imaging options recognizing cancer grades and types. The aim of this study is to optimize breast cancer diagnostic decisions based on cancer types using a large‐scale finite‐horizon Markov decision process (MDP) model with 4.6 million states to help reduce overdiagnosis. We prove the optimality of a divide‐and‐search algorithm that relies on tight upper bounds on the optimal decision thresholds to find an exact optimal solution. We project the high‐dimensional MDP onto two lower dimensional MDPs and obtain feasible upper bounds on the optimal decision thresholds. We use real data from two private mammography databases and demonstrate our model performance through a previously validated simulation model that has been used by the policy makers to set the national screening guidelines in the United States. We find that a decision‐analytical framework optimizing diagnostic decisions while accounting for breast cancer types has a strong potential to improve the quality of life and alleviate the immense costs of overdiagnosis. Our model leads to a [Formula: see text] reduction in overdiagnosis on the screening population, which translates into an annual savings of approximately $300 million for the U.S. health care system.
format Online
Article
Text
id pubmed-9313854
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93138542022-07-30 A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis Tunç, Sait Alagoz, Oguzhan Burnside, Elizabeth S. Prod Oper Manag Original Articles Overdiagnosis of breast cancer, defined as diagnosing a cancer that would otherwise not cause symptoms or death in a patient's lifetime, costs U.S. health care system over $1.2 billion annually. Overdiagnosis rates, estimated to be around 10%–40%, may be reduced if indolent breast findings can be identified and followed with noninvasive imaging rather than biopsy. However, there are no validated guidelines for radiologists to decide when to choose imaging options recognizing cancer grades and types. The aim of this study is to optimize breast cancer diagnostic decisions based on cancer types using a large‐scale finite‐horizon Markov decision process (MDP) model with 4.6 million states to help reduce overdiagnosis. We prove the optimality of a divide‐and‐search algorithm that relies on tight upper bounds on the optimal decision thresholds to find an exact optimal solution. We project the high‐dimensional MDP onto two lower dimensional MDPs and obtain feasible upper bounds on the optimal decision thresholds. We use real data from two private mammography databases and demonstrate our model performance through a previously validated simulation model that has been used by the policy makers to set the national screening guidelines in the United States. We find that a decision‐analytical framework optimizing diagnostic decisions while accounting for breast cancer types has a strong potential to improve the quality of life and alleviate the immense costs of overdiagnosis. Our model leads to a [Formula: see text] reduction in overdiagnosis on the screening population, which translates into an annual savings of approximately $300 million for the U.S. health care system. John Wiley and Sons Inc. 2022-03-08 2022-05 /pmc/articles/PMC9313854/ /pubmed/35915601 http://dx.doi.org/10.1111/poms.13691 Text en © 2022 The Authors. Production and Operations Management published by Wiley Periodicals LLC on behalf of Production and Operations Management Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tunç, Sait
Alagoz, Oguzhan
Burnside, Elizabeth S.
A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
title A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
title_full A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
title_fullStr A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
title_full_unstemmed A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
title_short A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
title_sort new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313854/
https://www.ncbi.nlm.nih.gov/pubmed/35915601
http://dx.doi.org/10.1111/poms.13691
work_keys_str_mv AT tuncsait anewperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis
AT alagozoguzhan anewperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis
AT burnsideelizabeths anewperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis
AT tuncsait newperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis
AT alagozoguzhan newperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis
AT burnsideelizabeths newperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis